Iron & Vitamin C Study
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Iron overload is a life-threatening condition that can lead to liver disease, cardiac disease, diabetes and arthritis. Simultaneous supplementation with both iron and AA may place individuals with SCI at risk for iron overload as well as oxidative damage by iron-generated free radicals. Both conditions of high and low iron stores may present with common signs and symptoms. Accurate diagnosis of iron disorder should consider CRP, hematocrit, hemoglobin, serum iron, TIBC, percent saturation of iron binding capacity, serum ferritin and hepcidin.
The investigators are proposing a study to determine the effect of concurrent AA and iron supplementation on iron status of individuals with SCI. The investigators goal is to identify abnormal status that may be attributed to simultaneous supplementation of iron and AA to develop future supplementation protocols in this population for optimal iron status.
| Condition |
|---|
|
Spinal Cord Injury |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Implications of Concurrent Iron and Ascorbic Acid Supplementation on Iron Status in Persons With Spinal Cord Injury |
- To determine iron status if supplemented with ascorbic acid (AA) and/or iron compared to supplementation with iron or AA. [ Time Frame: 1 episode, at least 6 months after consistent ascorbic acid and/or iron supplementation ] [ Designated as safety issue: No ]
- Determine the prevalence of high iron status if receiving supplementation with both iron and AA compared to supplementation with iron or AA. [ Time Frame: 1 episode, at least 6 months after consistent ascorbic acid and/or iron supplementation. ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood samples will be obtained for analysis.
| Estimated Enrollment: | 60 |
| Study Start Date: | June 2008 |
| Study Completion Date: | June 2011 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Group 1
Ascorbic Acid Supplementation Only
|
|
Group 2
Iron Supplementation Only
|
|
Group 3
Concurrent Ascorbic Acid & Iron Supplementation
|
Eligibility| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
US Veterans with spinal cord injuries greater than 6 months who are located near Bronx, NY
Inclusion Criteria:
- Male
- 18 years to 90 years of age
- Medically stable
- Chronic SCI (>6 months post injury) without regard to the level or completeness of lesion
Supplementation with:
- A standard recommended dose of 120-200 mg oral elemental iron (tablet or liquid; ferrous sulfate, fumarate or gluconate forms) for a minimum of 6 months; or
- A standard recommended dose of 250-2,000 mg AA per day for a minimum of 6 months; or
- Both 120-200 mg oral elemental iron AND 250-2,000 mg AA per day for a minimum of 6 months.
- Veteran
Exclusion Criteria:
Acute cardiovascular, pulmonary or renal conditions
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT00881803 History of Changes |
| Other Study ID Numbers: | B4162C-6 |
| Study First Received: | March 25, 2009 |
| Last Updated: | May 21, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by Department of Veterans Affairs:
|
Spinal Cord Injuries Ascorbic Acid Vitamin C Iron Dietary Supplements |
Additional relevant MeSH terms:
|
Spinal Cord Injuries Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases Trauma, Nervous System Wounds and Injuries Ascorbic Acid Vitamins Iron |
Antioxidants Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protective Agents Physiological Effects of Drugs Micronutrients Growth Substances Trace Elements |
ClinicalTrials.gov processed this record on May 19, 2013